Sign in
Not yet recruitingPhase 3

Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours

Key facts

Who runs it
The First Affiliated Hospital of University of Science and Technology of China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
1,395 people, planned
Starts
Dec 2026
Expected to end
30 Apr 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tenecteplase
  • Endovascular Treatment
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Age ≥18 years
  • Clinical diagnosis of acute ischemic stroke with a disabling deficit and baseline NIHSS score ≥6 before randomization
  • Pre-stroke modified Rankin Scale score ≤2
  • Randomization within 24 hours of symptom onset or last known well, including wake-up and unwitnessed stroke
  • Eligible for intravenous thrombolysis and endovascular thrombectomy according to the trial criteria
  • Written informed consent from the patient or a legal representative
  • Primary MeVO confirmed by computed tomography angiography or magnetic resonance angiography and responsible for the acute neurological deficit, involving the co-dominant or non-dominant M2 segment (occluded branch diameter ≤2.0 mm), M3, anterior cerebral artery A1-A3, or posterior cerebral artery P1-P3
  • Anterior circulation occlusion within 6 hours: established infarct extent <50% of the territory supplied by the occluded artery on non-contrast CT or diffusion-weighted MRI. For M2 or M3 occlusion, Alberta Stroke Program Early CT Score (ASPECTS) ≥6 is also required
  • Posterior circulation occlusion within 24 hours: posterior circulation ASPECTS (pc-ASPECTS) ≥8 and established infarct extent <50% of the territory supplied by the occluded artery on non-contrast CT or diffusion-weighted MRI
  • Anterior circulation occlusion at >6 to 24 hours, meeting either of the following imaging profiles: (a) established infarction involving <50% of the vascular territory corresponding to the clinical deficit on non-contrast CT or diffusion-weighted MRI; OR (b) target mismatch on CT or MR perfusion, defined as a mismatch volume >10 mL and a mismatch ratio >1.4

Who cannot take part

  • Suspected or previous cerebral vasculitis or infective endocarditis, including suspected septic embolism
  • Use of a direct thrombin inhibitor or a direct factor Xa inhibitor within 48 hours, unless dabigatran has been reversed with idarucizumab
  • Current participation in another interventional clinical trial, or participation within the previous 3 months in a study involving an investigational drug or device that could affect the present study
  • Intracranial hemorrhage on CT or MRI; fewer than 10 cerebral microbleeds on MRI are permitted
  • Pre-existing neurological disease or psychiatric disorder that precludes reliable examination or follow-up assessment
  • Known allergy to tenecteplase or its excipients; a contraindication to contrast agents, such as severe contrast allergy; or known allergy to nickel-titanium alloys or other materials used in thrombectomy devices
  • Severe cardiac or hepatic dysfunction or another serious systemic disease with a life expectancy of less than 1 year
  • History of arteriovenous malformation or aneurysm; intracranial tumor
  • Seizure at stroke onset that precludes an accurate baseline NIHSS assessment, or Todd paresis
  • History of drug or alcohol abuse or dependence that, in the investigator's judgment, would interfere with adherence to study requirements
  • Contraindication to thrombolysis, including intracranial hemorrhage or acute ischemic stroke within the previous 3 months; intracranial surgery or severe head trauma within 3 months; any previous intracranial hemorrhage; clinically suspected subarachnoid hemorrhage; arterial puncture at a non-compressible site within 7 days; major surgery or serious trauma within 14 days; gastrointestinal or urinary tract hemorrhage within 21 days; active internal bleeding or an acute bleeding tendency; hereditary or acquired bleeding diathesis or clotting-factor deficiency; platelet count <100 × 10⁹/L; current therapeutic-dose heparin anticoagulation (including therapeutic-dose low-molecular-weight heparin within 24 hours); international normalized ratio >1.7 or prothrombin time >15 seconds after anticoagulant use; or full-dose heparin or heparinoid use within 24 hours with an activated partial thromboplastin time above the upper limit of normal
  • Blood glucose <2.8 or >22.2 mmol/L
  • Renal impairment with estimated glomerular filtration rate <30 mL/min/1.73 m² or creatinine >176.8 µmol/L, or a requirement for dialysis
  • Intravenous thrombolysis already administered at a referring center
  • Rapidly improving neurological deficit, as judged by the investigator
  • Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg despite antihypertensive treatment
  • Medium vessel occlusion arising from distal migration or fragmentation of a more proximal thrombus, whether spontaneous, after intravenous thrombolysis, or during endovascular thrombectomy
  • Established infarction involving the arterial territory proximal to the target occlusion
  • Hypodensity on non-contrast CT exceeding the perfusion lesion, suggesting distal thrombus migration
  • Severe tortuosity, anatomical variant, or dissection precluding device access to the target vessel
  • Simultaneous occlusion in more than one vascular territory, such as anterior and posterior circulation occlusion or bilateral anterior circulation occlusion
  • Pregnancy or breastfeeding, or a positive pregnancy test before enrollment in a woman of childbearing potential
  • Inability to complete the 90-day follow-up (e.g., no fixed residence or living overseas)
  • Prisoners or incarcerated persons

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial compares intravenous thrombolysis (IVT) alone, endovascular treatment (EVT) alone, and bridging therapy (IVT followed immediately by EVT) in patients with acute ischemic stroke due to medium vessel occlusion (MeVO) and a baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6. The hypotheses are that EVT alone and bridging therapy each increase the proportion of patients with functional independence at 90 days compared with IVT alone. This is a multicenter, prospective, randomized, open-label trial with blinded outcome assessment. Patients will be randomized 1:1:1 within 24 hours of symptom onset or last known well. The primary outcome is functional independence, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days.

The 3 groups in the trial

  • IVT AloneExisting treatment, for comparison

    Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus. Endovascular treatment is not performed.

    Treatment: Tenecteplase

  • EVT AloneTreatment being tested

    Participants receive endovascular treatment without intravenous thrombolysis.

    Treatment: Endovascular Treatment

  • Bridging IVT Plus EVTTreatment being tested

    Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, followed immediately by endovascular treatment.

    Treatment: Tenecteplase and Endovascular Treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial
Record updated
12 November 2026